DRREDDYPharmaceuticals
Dr Reddys Laboratories Ltd — Cash Flow Statement
₹1254.90
-1.46%
Dr Reddys Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 1.20K Cr | 1.80K Cr | 4.00K Cr | 905.90 Cr | — |
| Repurchase Of Capital Stock | -138.90 Cr | 0.00 | 0.00 | 0.00 | — |
| Repayment Of Debt | -129.40 Cr | -494.70 Cr | -101.50 Cr | -78.50 Cr | — |
| Issuance Of Debt | 0.00 | 380.00 Cr | 0.00 | 0.00 | — |
| Issuance Of Capital Stock | 19.30 Cr | 80.50 Cr | 36.80 Cr | 33.40 Cr | — |
| Capital Expenditure | -3.44K Cr | -2.74K Cr | -1.89K Cr | -1.90K Cr | — |
| End Cash Position | 1.46K Cr | 710.70 Cr | 577.90 Cr | 1.49K Cr | — |
| Beginning Cash Position | 710.70 Cr | 577.90 Cr | 1.49K Cr | 1.48K Cr | — |
| Effect Of Exchange Rate Changes | 22.40 Cr | -5.90 Cr | 28.60 Cr | 73.30 Cr | — |
| Changes In Cash | 726.20 Cr | 138.70 Cr | -935.90 Cr | -70.10 Cr | — |
| Financing Cash Flow | 1.89K Cr | -376.30 Cr | -2.69K Cr | -242.20 Cr | — |
| Cash Flow From Continuing Financing Activities | 1.89K Cr | -376.30 Cr | -2.69K Cr | -242.20 Cr | — |
| Net Other Financing Charges | 705.60 Cr | — | — | — | — |
| Interest Paid Cff | -348.30 Cr | -226.60 Cr | -185.30 Cr | -134.50 Cr | — |
| Cash Dividends Paid | -666.20 Cr | -664.80 Cr | -497.90 Cr | -414.60 Cr | — |
| Net Common Stock Issuance | -119.60 Cr | 80.50 Cr | 36.80 Cr | 33.40 Cr | — |
| Common Stock Payments | -138.90 Cr | 0.00 | 0.00 | 0.00 | — |
| Common Stock Issuance | 19.30 Cr | 80.50 Cr | 36.80 Cr | 33.40 Cr | — |
| Net Issuance Payments Of Debt | 2.32K Cr | 434.60 Cr | -2.04K Cr | 273.50 Cr | — |
| Net Short Term Debt Issuance | 2.45K Cr | 549.30 Cr | -1.94K Cr | 352.00 Cr | — |
| Net Long Term Debt Issuance | -129.40 Cr | -114.70 Cr | -101.50 Cr | -78.50 Cr | — |
| Long Term Debt Payments | -129.40 Cr | -494.70 Cr | -101.50 Cr | -78.50 Cr | — |
| Long Term Debt Issuance | 0.00 | 380.00 Cr | 0.00 | 0.00 | — |
| Investing Cash Flow | -5.81K Cr | -4.03K Cr | -4.14K Cr | -2.64K Cr | — |
| Cash Flow From Continuing Investing Activities | -5.81K Cr | -4.03K Cr | -4.14K Cr | -2.64K Cr | — |
| Interest Received Cfi | 337.20 Cr | 133.80 Cr | 77.70 Cr | 87.30 Cr | — |
| Dividends Received Cfi | 0.00 | 44.50 Cr | 0.00 | 0.00 | — |
| Net Investment Purchase And Sale | 2.51K Cr | -1.57K Cr | -2.34K Cr | -1.12K Cr | — |
| Sale Of Investment | 27.96K Cr | 12.98K Cr | 11.28K Cr | 7.78K Cr | — |
| Purchase Of Investment | -25.45K Cr | -14.55K Cr | -13.62K Cr | -8.90K Cr | — |
| Net Business Purchase And Sale | -5.34K Cr | -1.20 Cr | 0.00 | -32.60 Cr | — |
| Purchase Of Business | -5.34K Cr | -1.20 Cr | 0.00 | -32.60 Cr | — |
| Net Intangibles Purchase And Sale | -616.20 Cr | -1.10K Cr | -754.30 Cr | -144.30 Cr | — |
| Sale Of Intangibles | 73.20 Cr | 2.10 Cr | 0.00 | 294.60 Cr | — |
| Purchase Of Intangibles | -689.40 Cr | -1.10K Cr | -754.30 Cr | -438.90 Cr | — |
| Net PPE Purchase And Sale | -2.70K Cr | -1.53K Cr | -1.12K Cr | -1.43K Cr | — |
| Sale Of PPE | 51.20 Cr | 106.40 Cr | 8.20 Cr | 37.00 Cr | — |
| Purchase Of PPE | -2.75K Cr | -1.64K Cr | -1.13K Cr | -1.47K Cr | — |
| Operating Cash Flow | 4.64K Cr | 4.54K Cr | 5.89K Cr | 2.81K Cr | — |
| Cash Flow From Continuing Operating Activities | 4.64K Cr | 4.54K Cr | 5.89K Cr | 2.81K Cr | — |
| Taxes Refund Paid | -2.00K Cr | -2.00K Cr | -1.07K Cr | -743.70 Cr | — |
| Change In Working Capital | -3.00K Cr | -2.02K Cr | -785.50 Cr | -1.85K Cr | — |
| Change In Other Working Capital | -729.30 Cr | 285.70 Cr | 52.80 Cr | 401.40 Cr | — |
| Change In Payables And Accrued Expense | 34.00 Cr | 346.00 Cr | 2.30 Cr | 441.20 Cr | — |
| Change In Payable | 34.00 Cr | 346.00 Cr | 2.30 Cr | 441.20 Cr | — |
| Change In Inventory | -1.28K Cr | -1.84K Cr | -265.40 Cr | -991.20 Cr | — |
| Change In Receivables | -1.03K Cr | -805.40 Cr | -575.20 Cr | -1.70K Cr | — |
| Other Non Cash Items | 15.20 Cr | -56.70 Cr | 24.80 Cr | -0.70 Cr | — |
| Stock Based Compensation | 42.40 Cr | 40.70 Cr | 39.70 Cr | 59.20 Cr | — |
| Unrealized Gain Loss On Investment Securities | -355.40 Cr | -314.90 Cr | -87.60 Cr | -27.70 Cr | — |
| Provisionand Write Offof Assets | 16.10 Cr | 27.50 Cr | 20.50 Cr | 5.50 Cr | — |
| Asset Impairment Charge | 691.30 Cr | 356.60 Cr | 556.80 Cr | 1.21K Cr | — |
| Deferred Tax | 1.95K Cr | 1.62K Cr | 1.53K Cr | 873.00 Cr | — |
| Deferred Income Tax | 1.95K Cr | 1.62K Cr | 1.53K Cr | 873.00 Cr | — |
| Depreciation Amortization Depletion | 1.71K Cr | 1.48K Cr | 1.26K Cr | 1.18K Cr | — |
| Depreciation And Amortization | 1.71K Cr | 1.48K Cr | 1.26K Cr | 1.18K Cr | — |
| Amortization Cash Flow | 655.30 Cr | 526.50 Cr | — | — | — |
| Amortization Of Intangibles | 655.30 Cr | 526.50 Cr | — | — | — |
| Depreciation | 1.05K Cr | 957.60 Cr | — | — | — |
| Operating Gains Losses | -152.80 Cr | -158.10 Cr | -110.10 Cr | -258.80 Cr | — |
| Earnings Losses From Equity Investments | -21.70 Cr | -14.70 Cr | -37.00 Cr | -70.30 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 21.10 Cr | -53.40 Cr | -93.90 Cr | -76.60 Cr | — |
| Net Income From Continuing Operations | 5.72K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Short Term Debt Payments | — | — | -1.94K Cr | — | — |
| Capital Expenditure Reported | — | — | -1.89K Cr | -1.90K Cr | -1.26K Cr |
| Short Term Debt Issuance | — | — | — | 352.00 Cr | 679.10 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Dr Reddys Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.